CRISPR tool makes 'immune-cold' prostate cancer respond to immunotherapy in mice
New CapabilitiesAn RNA-targeting gene editor switched a hidden immune 'flag' back on, drawing immune cells into tumors that normally ignore checkpoint drugs.
July 26th, 2026: Findings reach wider coverageNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated Jul 26Immunotherapy has changed cancer treatment over the past 15 years, but prostate tumors barely respond to it. Researchers have now found a way to make these 'cold' tumors visible to the immune system, at least in mice.
A team led by Duke University and University of Rochester scientists used an RNA-targeting version of CRISPR to switch a molecular 'flag' back on inside prostate cancer cells. That flag let immune cells find the tumor and made existing checkpoint drugs work far better. The results are early and have not been tested in people.
Why it matters
Prostate cancer kills about 35,000 American men a year and mostly shrugs off immunotherapy. This tool could crack that resistance, if it works in humans.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
The Rochester, New York medical center whose RNA Biology team helped build and test the gene-editing tool.
The North Carolina medical school whose scientists led the design of the RNA-based CRISPR therapy.
Timeline
April 2010 July 2026
-
Findings reach wider coverage
Latest StatementResearchers describe the approach as a possible route to treating 'immune-cold' cancers, while stressing the results are early and not yet tested in humans.
-
RNA-based CRISPR tool published
ResearchDuke and Rochester scientists report in Nature Biomedical Engineering that a Cas13 tool restores the MHC-I immune 'flag' on prostate tumors and boosts checkpoint therapy in mice.
-
Pembrolizumab cleared for a genetic subset
RegulatoryThe FDA approves the checkpoint drug pembrolizumab for tumors with specific DNA-repair defects, covering only a small slice of prostate cancer patients.
-
First prostate cancer immunotherapy approved
RegulatoryThe FDA approves sipuleucel-T, a cell-based vaccine for advanced prostate cancer. It extends survival modestly and shows how hard the disease is to treat with the immune system.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Sipuleucel-T approval (2010)
The FDA approved sipuleucel-T, the first therapeutic cancer vaccine, for advanced prostate cancer. It trained a patient's own immune cells to attack the tumor. The survival benefit was measured in months.
It proved the immune system could be turned against prostate cancer, but the effect was small and the treatment costly and complex.
The drug saw limited use and showed how stubbornly 'cold' prostate tumors resist immune attack.
It marks the start of a 15-year effort to make immunotherapy work in prostate cancer, the problem the new tool tries to solve.
Ipilimumab in melanoma (2011)
The FDA approved ipilimumab, the first checkpoint inhibitor, for advanced melanoma. Melanoma is a 'hot' tumor, riddled with mutations that flag it to the immune system. Some patients saw long-lasting remissions.
Checkpoint drugs became a standard treatment for melanoma and lung cancer.
Their success in 'hot' tumors sharpened the puzzle of why 'cold' tumors like prostate and pancreatic cancer barely respond.
The new tool aims to convert a cold tumor into something closer to the hot tumors where checkpoint drugs already work.
CAR-T cells hit a wall in solid tumors (2017)
The FDA approved the first CAR-T cell therapy, which re-engineers a patient's T cells to hunt cancer. It produced striking cures in some blood cancers. In solid tumors, the same cells struggled to find and enter the mass.
CAR-T became a powerful option for certain leukemias and lymphomas.
Its failure against solid tumors focused research on the barriers that keep immune cells out, including missing 'flags' like MHC-I.
The new work targets exactly that barrier, restoring the MHC-I flag so immune cells can recognize a solid tumor.
